Protagonist Therapeutics (PTGX) Stock Price, Quote, News & History | Benzinga

Protagonist Therapeutics Inc (PTGX) Stock Price, Quote, News & History

PTGXNASDAQ

Trade with Public

Trade with Public

$151.50

0.910.6%

At close: Aug 25, 5:00 PM EST

$151.50

0.910.6%

Pre-Market: 4:49 AM EST

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

-

Close

$151.50

Volume / Avg.

200.00 / 681.85K

Day Range

- - -

52 Wk Range

54.50 - 160.81

Market Cap

$9.80B

P/E Ratio

147.27

Dividend Yield

-

Exchange

NASDAQ

RSI

59

Short Interest

13.99%

Days to Cover

16.42

Recent Protagonist Therapeutics, Inc. News

Royalty Pharma Locks in $100M Zealand Pharma Funding Pact for Blood Disorder Drug

Royalty Pharma will pay Zealand Pharma $100 million for economic rights tied to rusfertide, with FDA action expected in Q3 of 2026.

Vandana Singh

This NetApp Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Monday

Wall Street analysts upgraded PTGX, LECO, and JHX. See analyst ratings and price targets for these stocks.

Avi Kapoor

This $300 Million Biotech May Be Deeply Mispriced: Analyst

Silence Therapeutics ($SLN) stock surges as Cantor predicts key August Phase 2 data will be a major catalyst in the PV market.

Vandana Singh

AbbVie Expands Immunology Footprint With Apogee $11 Billion Acquisition

AbbVie will acquire Apogee for $10.9 billion, adding late-stage immunology and asthma assets to its pipeline.

Vandana Singh

Silence Therapeutics Stock Rises On Positive Blood Cancer Drug Data

Silence Therapeutics says SANRECO data show sustained polycythemia vera benefits as analysts weigh divesiran's profile against rusfertide.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

131.20M

Investing Cash Flow (TTM)

78.72M

Financing Cash Flow (TTM)

41.61M

Free Cash Flow (TTM)

130.58M

Capital Expenditure (TTM)

-615.00K

Net Change in Cash (TTM)

251.53M

Analyst Trends and Forecast

4

1

Mar

2

Apr

1

May

2

Jul

6

Aug

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.3

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$9.04B

PE Ratio (TTM)

147.27

PE Ratio (FWD)

37.88

PEG Ratio (TTM)

-

PS Ratio (TTM)

36.24

PB Ratio (TTM)

11.66

Earnings Yield % (TTM)

0.68%

Earnings Yield % (FWD)

2.64%

EV / EBITDA (TTM)

151.00

Price / EBITDA (TTM)

170.64

Price / Free Cash Flow (TTM)

78.25

Book Value / Share

$13.01

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$420.08M

Debt to Equity

0.01

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

-

Close

$151.50

Volume / Avg.

200.00 / 681.85K

Day Range

- - -

52 Wk Range

54.50 - 160.81

Market Cap

$9.80B

P/E Ratio

147.27

Dividend Yield

-

Exchange

NASDAQ

RSI

59

Short Interest

13.99%

Days to Cover

16.42

About

Sector

Health Care

Industry

Biotechnology

Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology,...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS better than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS better than industry

FAQ

Q

How do I buy Protagonist Therapeutics (PTGX) stock?

A

You can purchase shares of Protagonist Therapeutics (NASDAQ:PTGX) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Protagonist Therapeutics (PTGX) competitors?

A

Other companies in Protagonist Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Q

What is the forecast, or price target, for Protagonist Therapeutics (PTGX) stock?

A

Protagonist Therapeutics has a consensus price target of $122.88.

Q

What is the current price for Protagonist Therapeutics (PTGX)?

A

The stock price for Protagonist Therapeutics (NASDAQ: PTGX) is $151.5 last updated August 27, 2026 at 4:49 AM EDT.

Q

Does Protagonist Therapeutics (PTGX) pay a dividend?

A

There are no upcoming dividends for Protagonist Therapeutics.

Q

When is Protagonist Therapeutics (NASDAQ:PTGX) reporting earnings?

A

Protagonist Therapeutics does not have any upcoming earnings scheduled.

Q

Is Protagonist Therapeutics (PTGX) going to split?

A

There is no upcoming split for Protagonist Therapeutics.

Q

What sector and industry does Protagonist Therapeutics (PTGX) operate in?

A

Protagonist Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.